The Effects of Rosiglitazone, Metformin, and Estradiol-Cyproterone Acetate on Lean Patients With Polycystic Ovary Syndrome


ÇETİNKALP Ş. , KARADENİZ M. , ERDOĞAN M. , ÖZGEN A. G. , SAYGILI L. F. , YILMAZ C.

ENDOCRINOLOGIST, cilt.19, ss.94-97, 2009 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 19 Konu: 3
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1097/ten.0b013e3181a58772
  • Dergi Adı: ENDOCRINOLOGIST
  • Sayfa Sayıları: ss.94-97

Özet

Background: Polycystic ovary syndrome (PCOS) is characterized by anovulation, infertility, and hyperandrogenism. The present study aims to compare the clinical, biochemical, and hormonal changes in PCOS patients taking estradiol-cyproterone acetate (ECA), metformin (MET), and rosiglitazone (ROSI).